Initiator Pharma (INIT) investor relations material

Strategic and financial overview

• Advancing monoamine modulating drugs for sexual dysfunctions and pain, with Pudafensine as the lead candidate showing efficacy and safety in clinical trials.

• Well-financed through 2027, with a focus on securing global or regional partnerships, especially with big pharma, to support further clinical development and commercialization.

• Business development efforts are concentrated on erectile dysfunction (ED), vulvodynia (neuropathic pain in women), and female sexual dysfunction, with multiple inflection points expected in the next 12-14 months.

• Clinical resources are currently prioritized for vulvodynia, with ongoing Phase IIA trials and anticipated top-line data by the end of 2026.

• Plans for further ED studies hinge on partnership agreements due to the scale and investment required.

Clinical and market highlights

• Pudafensine demonstrated efficacy in Phase IIB ED trials, meeting primary endpoints and showing a favorable safety profile with no significant side effects or drug-drug interactions.

• Addresses a significant unmet need: 30%-40% of ED patients do not respond to current PDE5 therapies, and over 31 million women in the US and Europe suffer from vulvodynia with no approved treatments.

• Vulvodynia trial uses validated FDA/EMA endpoints, with a randomized, double-blind, placebo-controlled design; readout expected in Q4 2026.

• Pudafensine offers a differentiated mechanism by modulating dopamine centrally and peripherally, potentially inducing natural sexual response and providing pain relief.

• Commercial opportunity estimated at $1–$4 billion in annual peak sales for vulvodynia, with potential for premium pricing in ED due to targeting non-responders.

Partnership and commercialization strategy

• Actively pursuing both global and regional partnerships, with interest from companies in women's health, pain, and ED across the US, Europe, and Asia.

• ED partnerships likely with established branded product players, while vulvodynia may attract both global and regional women's health and pain-focused companies.

• Commercial launch strategies are opportunistic, with the US prioritized for vulvodynia and Asia (Japan, China) considered attractive for ED due to market preferences.

• Partnership deals are expected to support large-scale clinical trials and commercialization, with flexibility to structure agreements regionally or globally.

• Investors are encouraged by the unique clinical profile of Pudafensine, large addressable markets, and upcoming clinical and business milestones.